HVIVO PLC (HVO) — Company Presentation

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the HVIVO PLC Investor Update. Throughout today's presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Please simply type in your questions at any time and press send. Given the attendance on today's call, the company may not be in a position to answer every question they received during the meeting itself. However, the company can review your questions and we'll publish those responses where it's appropriate to do so. Before we begin, we'd like to submit the following poll, and I'm sure the company will be most grateful for your participation. I'd now like to hand over to CEO, Mokar. Mo, good afternoon. Good afternoon or good evening. Thank you very much for for the kind introduction, and welcome to everyone out there in the audience. You are here to listen to our 2024 update and also the the announcement of our first acquisition in our m and a strategy. So without further ado, we'll drill straight into it. This is our normal compulsory disclaimer. I'm Yami Mohan. I'm the CEO of HVIVO. I've been here just just under three years. Like, my anniversary is coming up in the next couple of weeks. I'm here with Steven. So I'm Steven. I've been with the company for now eight years. So we've we've had a good year. And he's our CFO. Yeah. Okay. So just drilling straight into presence. So you already know we have a fairly large presence here in in The UK with our 50 bed facility in in in London where we're sitting at the moment. We also have Ben Life Sciences with presence in in The Netherlands and also in France, in Paris. Now we've just completed the acquisition of two clinical research units ...